Keith D Wilner

Keith D Wilner

UNVERIFIED PROFILE

Are you Keith D Wilner?   Register this Author

Register author
Keith D Wilner

Keith D Wilner

Publications by authors named "Keith D Wilner"

Are you Keith D Wilner?   Register this Author

39Publications

1277Reads

36Profile Views

Systematic review and network meta-analysis of first-line therapy for advanced -positive non-small-cell lung cancer.

Future Oncol 2019 Aug 12;15(24):2857-2871. Epub 2019 Jul 12.

Pfizer, Sollentuna, 191 90, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0270DOI Listing
August 2019

Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer.

Cancer Chemother Pharmacol 2019 Jul 24;84(1):203-211. Epub 2019 May 24.

Clinical Pharmacology, Global Product Development, Pfizer Inc, 10555 Science Center Drive, CB10/002/2533, San Diego, CA, 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03861-yDOI Listing
July 2019

Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC.

J Thorac Oncol 2019 Jun 26;14(6):1077-1085. Epub 2019 Feb 26.

Pfizer Oncology, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.015DOI Listing
June 2019

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 10 14;13(10):1539-1548. Epub 2018 Aug 14.

Department of Clinical Oncology, State Laboratory of South China, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.06.012DOI Listing
October 2018

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 08 16;36(22):2251-2258. Epub 2018 May 16.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Tony S. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Osaka, Japan; Tarek Mekhail, Florida Hospital, Orlando, FL; Enriqueta Felip, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Federico Cappuzzo, Azienda Unità Sanitaria Locale Della Romagna, Ravenna; Jolanda Paolini and Tiziana Usari, Pfizer Oncology, Milan, Italy; Yiyun Tang and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; and Fiona Blackhall, Manchester University, and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.4794DOI Listing
August 2018

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.

Cancer Res Treat 2018 Jul 6;50(3):691-700. Epub 2017 Jul 6.

State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2017.280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984PMC
July 2018

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 05 29;36(14):1405-1411. Epub 2018 Mar 29.

Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Shun Lu, Jiao Tong University, Shanghai; Jianying Zhou, First Affiliated Hospital of Zhejiang University, Hangzhou, People's Republic of China; James Chih-Hsin Yang, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Republic of China; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center, Seoul, South Korea; Takashi Seto, National Kyushu Cancer Center, Fukuoka; Noboru Yamamoto, National Cancer Center Hospital, Tokyo; Toshiaki Takahashi, Shizuoka Cancer Center, Shizuoka; Takeharu Yamanaka, Yokohama City University School of Medicine, Yokohama; Koichi Goto, National Cancer Center Hospital East, Kashiwa, Japan; Allison Kemner and Debasish Roychowdhury, OxOnc Development, Princeton, NJ; Nirvan Consultants, Lexington, MA; Jolanda Paolini and Tiziana Usari, Pfizer, Milan, Italy; and Keith D. Wilner, Pfizer, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5587DOI Listing
May 2018

Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials.

Clin Lung Cancer 2017 09 14;18(5):472-479. Epub 2017 Mar 14.

Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Sacramento, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.03.004DOI Listing
September 2017

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

J Clin Oncol 2016 08 28;34(24):2858-65. Epub 2016 Mar 28.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Federico Cappuzzo, Istituto Toscano Tumori, Livorno; Jolanda Paolini, Jennifer Tursi, and Tiziana Usari, Pfizer Oncology, Milan, Italy; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Fiona H. Blackhall, The Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom; Daniel B. Costa, Beth Israel Deaconess Center, Boston, MA; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Keith D. Wilner and Paulina Selaru, Pfizer Oncology, La Jolla, CA; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Kazuhiko Nakagawa, Kinki University, Osaka, Japan; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangzhou, China; and Tony S.K. Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.5888DOI Listing
August 2016

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

J Clin Oncol 2015 Jun 26;33(17):1881-8. Epub 2015 Jan 26.

Daniel B. Costa, Beth Israel Deaconess Medical Center, Harvard Medical School; Alice T. Shaw, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Sai-Hong I. Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Irvine; S. Martin Shreeve, Paulina Selaru, and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Gregory J. Riely, Memorial Sloan-Kettering Cancer Center; Patrick Schnell, Pfizer Oncology, New York, NY; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea; Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China; Anna Polli, Pfizer Oncology, Milan; Lucio Crinò, Perugia University Medical School, Perugia, Italy; Robin Wiltshire, Pfizer Oncology, Tadworth, United Kingdom; and D. Ross Camidge, University of Colorado Denver, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451171PMC
June 2015

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

N Engl J Med 2014 Dec;371(23):2167-77

From Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin (T. Mok), and Guangdong Lung Cancer Institute, Guangzhou (Y.-L.W.) - both in China; Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Kinki University, Osaka, Japan (K.N.); Florida Hospital Cancer Institute, Orlando (T. Mekhail); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (E.F.); Istituto Toscano Tumori, Livorno (F.C.), and Pfizer Oncology, Milan (J.P., T.U., J.T.) - both in Italy; Pfizer Oncology (S.I.) and Pfizer Global Innovative Pharma Business (A.R.) - both in New York; Pfizer Oncology, La Jolla, CA (K.D.W.); and the Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom (F.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1408440DOI Listing
December 2014

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Nov 27;371(21):1963-71. Epub 2014 Sep 27.

From the Massachusetts General Hospital Cancer Center (A.T.S., L.P.L., Z.Z., J.W.C., A.J.I.), Dana-Farber Cancer Institute (G.I.S.), and Beth Israel Deaconess Medical Center (D.B.C.) - all in Boston; University of California at Irvine, Irvine (S.-H.I.O.), and Pfizer Oncology, La Jolla (W.T., S.M.S., L.M.T., J.G.C., K.D.W.) - both in California; Seoul National University Hospital, Seoul, South Korea (Y.-J.B.); University of Colorado, Aurora (D.R.C., M.V.-G., R.C.D.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); University of Chicago, Chicago (R.S.); Memorial Sloan Kettering Cancer Center, New York (G.J.R.); Karolinska Institutet, Stockholm (Z.Z.); and Rho, Chapel Hill, NC (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264527PMC
November 2014

Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Nov;9(11):1625-33

*Department of Medical Oncology, Institute of Cancer Sciences, Manchester University, and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; †Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; ‡Department of Thoracic Oncology, Institut Gustave Roussy, Villejuif, France; §National Cancer Center Hospital, Tokyo, Japan; ‖Division of Translational & Clinical Research, Center for Lung Cancer, National Cancer Center, Goyang, South Korea; ¶Clinical Development, Pfizer Oncology, La Jolla, CA; #Biostatistics, Pfizer Global Innovative Pharma Business, New York, NY; **Global Outcomes & Evidence, Pfizer Oncology, New York, NY; ††Department of Oncology, McGill University Health Centre, Montreal, Canada; and ‡‡Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000318DOI Listing
November 2014

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

J Clin Oncol 2011 May 21;29(15):e443-5. Epub 2011 Mar 21.

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.34.1313DOI Listing
May 2011

Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.

Drug Metab Dispos 2011 Mar 23;39(3):383-93. Epub 2010 Nov 23.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, San Diego, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.110.035857DOI Listing
March 2011

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

J Thorac Oncol 2010 Dec;5(12):2044-6

Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of Irvine Medical Center, Orange, California 92868-3298, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318200f9ffDOI Listing
December 2010

Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.

J Clin Pharmacol 2005 Jun;45(6):620-30

Pfizer Global Research and Development, Groton, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270005276485DOI Listing
June 2005

Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers.

J Clin Pharmacol 2002 Sep;42(9):1027-30

Pfizer Global Research and Development, San Diego, California 92122, USA.

View Article

Download full-text PDF

Source
September 2002

The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery.

J Clin Psychopharmacol 2002 Apr;22(2):206-10

Department of Clinical Research, Pfizer Central Research, Groton, Connecticut 06340, USA.

View Article

Download full-text PDF

Source
April 2002

CP-101,606: An NR2B-Selective NMDA Receptor Antagonist.

CNS Drug Rev 1998 Dec;4(4):307-322

Central Research Division, Pfizer Inc., Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1527-3458.1998.tb00073.xDOI Listing
December 1998

Pharmacokinetics in Non-Insulin-Dependent Diabetics of the Aldose Reductase Inhibitor, Zopolrestat.

Am J Ther 1995 Feb;2(2):112-118

Central Research Division, Pfizer Inc., Groton, USA.

View Article

Download full-text PDF

Source
February 1995